PAHC insider files Form 144 to sell 264K Class A shares via Goldman Sachs

Rhea-AI Filing Summary

Phibro Animal Health Corporation (PAHC) filed a Form 144 reporting a proposed sale of 264,000 shares of Class A Common Stock through Goldman Sachs & Co. LLC with an approximate aggregate market value of $8,250,000. The filing lists 20,367,574 shares outstanding and an approximate sale date of 08/19/2025 on NASD. The shares were acquired on 04/14/2014 in a private placement from Phibro Animal Health Corporation, and the consideration is reported as an exchange of securities. The filer states there were no securities sold by the selling person in the past three months and includes the standard signature representation that the person does not possess undisclosed material adverse information.

Positive

• Complete procedural disclosure including broker, acquisition date, and nature of acquisition
• No sales in prior three months reported, indicating this is a discrete notice rather than frequent disposals
• Transaction routed through a major broker (Goldman Sachs & Co. LLC), supporting orderly execution

Negative

• Proposed sale of 264,000 shares equates to approximately 1.30% of outstanding shares based on numbers provided, which may increase supply pressure
• Transaction described as an exchange of securities rather than a cash purchase, adding complexity to the disposition

Insights

Securities Analyst

TL;DR: Routine Form 144 disclosing an insider sale of 264,000 shares valued at $8.25M; informational but not evidence of company distress.

The filing documents a proposed sale executed through a major broker with clear acquisition history: the shares were obtained in a 2014 private placement and are to be sold via exchange of securities. The size of the sale—264,000 shares against 20,367,574 outstanding—represents approximately 1.30% of outstanding shares based on the numbers provided. There were no reported sales in the prior three months, which supports this being a discrete planned transaction rather than a series of recent disposals. The disclosure is procedurally complete for a Rule 144 notice and provides necessary timelines and broker details.

Corporate Governance Expert

TL;DR: Standard compliance filing under Rule 144 showing an insider-originated sale; disclosure meets form requirements.

The notice includes required issuer and transaction details, acquisition source (private placement from the issuer) and the method of payment (exchange of securities). The filer affirms no material nonpublic information, and the absence of other sales in the past three months is explicitly stated. From a governance perspective, the filing appears procedurally appropriate and transparent; it does not by itself indicate compliance issues or governance changes.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	264000	8250000	20367574	08/19/2025	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common Stock	04/14/2014	Private placement from issuer of securities	Phibro Animal Health Corporation			264000	04/14/2014	Exchange of Securities

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by Phibro Animal Health Corporation (PAHC) report?

The Form 144 reports a proposed sale of 264,000 Class A Common Stock shares with an aggregate market value of $8,250,000, to be sold via Goldman Sachs & Co. LLC on or about 08/19/2025.

How were the 264,000 shares acquired according to the filing?

The shares were acquired on 04/14/2014 in a private placement from Phibro Animal Health Corporation and the consideration is listed as an exchange of securities.

Did the filer report any sales of PAHC securities in the past three months?

No. The filing explicitly states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

Through which broker will the proposed sale be executed?

The proposed sale is listed as being executed through Goldman Sachs & Co. LLC, located at 200 West Street, New York, NY 10282.

What representation does the signer make about material nonpublic information?

By signing the notice, the person represents that they do not know any material adverse information about the issuer that has not been publicly disclosed.